Industry: Pharmaceuticals, Biotechnology
Domantis is a drug discovery and development company that specializes in the smallest antibody fragments called Domain Antibodies (dAbs). These molecules are less than one tenth the size of conventional antibodies and combine the best attributes of small molecule drugs (formulation and delivery versatility, broad target range, low costs) with those of full antibodies (enormous diversity, high specificity, lower toxicity). Domantis was launched in December 2000 by Dr Greg Winter (also co-founder of Cambridge Antibody Technology Plc) and Dr Ian Tomlinson, who are globally recognized leaders and have over 35 years combined experience in the field of antibody ( www.domantis.com )
Domantis Limited
315 Cambridge Science Park Milton Road,
Cambridge, CB4 0WG
United Kingdom
Tel: +44 1223 226900
Fax: +44 1223 226901